Govt says Covid-19 drug Remdesivir will sell at set price, ups production

Gadkari on Thursday visited the Genetic Life Sciences (pharmacy) in Wardha to oversee the production of Remdesivir injections

The Centre has decided to increase production of anti-viral drug Remdesivir and it will be provided to people at government's price, said Union Minister Nitin Gadkari on Thursday.

This comes after several cases of blackmarketing of Remdesivir came to light amid the COVID-19.

"There was a shortage of Remdesivir injection. Because of this, incidents of black marketing took place, several people lost their lives as they have not received Remdesivir, so we decided to increase its production," Gadkari said.

"But we tried (and to got manufacturing rights), Remdesivir will be provided to people at government's price. Now, I think there will be no black marketing or no person will die due to lack of it, there is no reservation, can be provided to other states when there will be surplus," he added.

Gadkari on Thursday visited the Genetic Life Sciences (pharmacy) in Wardha to oversee the production of Remdesivir injections.

There are currently 35,66,398 active cases in the country, as per Union Health Ministry.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel